J&J's Stelara effective in psoriatic arthritis trial

June 11 (Reuters) - Johnson & Johnson's Stelara produced significant improvement in signs and symptoms of psoriatic arthritis through 52 weeks of treatment in a late stage study, according to data being presented at a medical meeting in Europe.